4.7 Article

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment

期刊

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00114-22

关键词

artesunate; malaria; Plasmodium falciparum; viability; antimicrobial activity; clinical trials; drug activity; preclinical drug studies

资金

  1. Bill & Melinda Gates Foundation [OPP1111147, INV-007155]
  2. National Health and Medical Research Council (NHMRC) of Australia
  3. Australian Research Council [DP180103875]
  4. NHMRC
  5. Bill and Melinda Gates Foundation [OPP1111147] Funding Source: Bill and Melinda Gates Foundation

向作者/读者索取更多资源

This study investigates the impact of artesunate on the viability of Plasmodium faciparum in humans and mice. The results show that artesunate leads to a faster decline in parasite viability compared to parasitemia. Higher concentrations of artesunate also result in faster parasite elimination. Predictions of infection recrudescence can be accurately made based on measures of parasite viability.
The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this metric does not distinguish between viable and nonviable parasites. Thus, enumeration of parasites may result in underestimation of drug activity for some compounds, potentially confounding its use as a metric for assessing antimalarial activity in vivo. Here, we report a study of the effect of artesunate on Plasmodium faciparum viability in humans and in mice. We first measured the drug effect in mice by estimating the decrease in parasite viability after treatment using two independent approaches to estimate viability. We demonstrate that, as previously reported in humans, parasite viability declines much faster after artesunate treatment than does the decline in parasitemia (termed parasite clearance). We also observed that artesunate kills parasites faster at higher concentrations, which is not discernible from the traditional parasite clearance curve and that each subsequent dose of artesunate maintains its killing effect. Furthermore, based on measures of parasite viability, we could accurately predict the in vivo recrudescence of infection. Finally, using pharmacometrics modeling, we show that the apparent differences in the antimalarial activity of artesunate in mice and humans are partly explained by differences in host removal of dead parasites in the two hosts. However, these differences, along with different pharmacokinetic profiles, do not fully account for the differences in activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据